The global Personal Care CMO And CDMO Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Product & Service (Assay Kits, Instruments, Services), By Circulating Biomarker (Circulating Tumor Cells, Circulating Tumor DNA, Cell-free DNA, Extracellular Vesicles, Others), By Clinical Application (Early Cancer Screening, Therapy Selection, Treatment Monitoring, Recurrence Monitoring), By Technology (Multi-gene Parallel Analysis using NGS, Single-gene Analysis using PCR), By Application (Cancer Applications, Non-cancer Applications), By End-User (Reference Laboratories, Hospitals and Physician Laboratories, Academic & Research Centers, Others).
The liquid biopsy market in 2025 continues to witness substantial growth driven by advancements in cancer diagnostics and personalized medicine. Liquid biopsy techniques, including circulating tumor DNA (ctDNA) analysis and circulating tumor cell (CTC) detection, offer minimally invasive and real-time monitoring of cancer biomarkers, enabling early detection, treatment response assessment, and therapeutic decision-making. With increased adoption in oncology clinics, research institutions, and pharmaceutical companies, the liquid biopsy market experiences innovations in assay sensitivity, multiplexing capabilities, and clinical utility, driving market expansion and enhancing cancer patient care globally.
The market report analyses the leading companies in the industry including Biocept Inc, Bio-Rad Laboratories Inc, Exact Sciences Corp, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina Inc, Mdxhealth, Myriad Genetics Inc, Natera Inc, Personalis Inc, Qiagen, Sysmex Corp, Thermo Fisher Scientific Inc.
The most prominent trend in the Liquid Biopsy Market is the advancements in molecular diagnostics and precision medicine. Liquid biopsy techniques, which involve analyzing biomarkers in bodily fluids such as blood, urine, and saliva, have gained traction due to their non-invasive nature and ability to provide real-time insights into a patient's health status. This trend encompasses the development of innovative liquid biopsy assays, adoption of next-generation sequencing technologies, and integration of liquid biopsy results into personalized treatment plans, driving the market growth in oncology, infectious diseases, and other medical specialties.
A significant driver for the Liquid Biopsy Market is the global shift towards early disease detection and monitoring. Liquid biopsies offer healthcare professionals a minimally invasive method to detect genetic mutations, circulating tumor cells, cell-free DNA, and other biomarkers indicative of diseases such as cancer, cardiovascular disorders, and infectious diseases. The ability to detect diseases at an early stage, monitor treatment response, track disease progression, and identify potential therapeutic targets drives the adoption of liquid biopsy techniques across healthcare settings.
One potential opportunity in the Liquid Biopsy Market lies in the expansion into companion diagnostics and drug development. Collaborating with pharmaceutical companies, biotech firms, and research institutions presents opportunities to develop liquid biopsy-based companion diagnostic tests for targeted therapies, immunotherapies, and personalized medicine approaches. Capitalizing on this opportunity involves validating liquid biopsy biomarkers for specific diseases, conducting clinical trials to demonstrate diagnostic accuracy and clinical utility, obtaining regulatory approvals for companion diagnostic assays, and partnering with stakeholders to integrate liquid biopsy insights into precision medicine strategies, thereby improving patient outcomes and advancing the field of molecular diagnostics.
The largest segment in the Liquid Biopsy Market is Therapy Selection. This segment is experiencing significant growth due to the rising demand for personalized medicine and targeted therapies in oncology. Liquid biopsy tests play a crucial role in identifying specific genetic mutations and biomarkers in circulating tumor DNA (ctDNA), which helps oncologists in selecting the most effective treatment strategies for individual cancer patients. As precision medicine continues to gain prominence in cancer care, the demand for liquid biopsy-based therapy selection tools is increasing, making it the largest segment in the market.
The fastest-growing segment in the Liquid Biopsy Market is Multi-gene Parallel Analysis using NGS (Next-Generation Sequencing). This growth is propelled by advancements in genomic analysis technologies and their applications in oncology. NGS-based liquid biopsy allows for the simultaneous analysis of multiple genes, offering comprehensive insights into tumor biology, drug resistance mechanisms, and treatment response prediction. As precision medicine evolves and the need for comprehensive genetic profiling increases, the demand for NGS-based liquid biopsy technologies is surging, making it the fastest-growing segment in the market.
The largest segment in the Liquid Biopsy Market is Cancer Applications. This segment encompasses a wide range of diagnostic and monitoring applications for various types of cancer, including lung, breast, colorectal, prostate, and others. Liquid biopsy for cancer applications involves the detection and analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), and other biomarkers in the blood, providing valuable insights into cancer diagnosis, treatment selection, response monitoring, and recurrence surveillance. The increasing prevalence of cancer worldwide and the growing adoption of liquid biopsy technologies for early detection and personalized treatment strategies contribute to the dominance of cancer applications in the liquid biopsy market.
The fastest-growing segment in the Liquid Biopsy Market is Hospitals and Physician Laboratories. This growth is driven by the increasing adoption of liquid biopsy techniques in hospital settings and physician laboratories for cancer diagnosis, treatment monitoring, and personalized medicine approaches. These facilities are leveraging liquid biopsy technologies to provide rapid and non-invasive diagnostic solutions, leading to improved patient outcomes and more targeted therapies. Additionally, advancements in liquid biopsy platforms and the rising demand for minimally invasive diagnostic methods further propel the growth of this segment within the liquid biopsy market.
By Product & Service
By Circulating Biomarker
By Clinical Application
By Technology
By Application
By End-User
Countries Analyzed
*- List Not Exhaustive
TABLE OF CONTENTS
1 Introduction to 2025 Lipid Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Lipid Market Size Outlook, $ Million, 2021 to 2030
3.2 Lipid Market Outlook by Type, $ Million, 2021 to 2030
3.3 Lipid Market Outlook by Product, $ Million, 2021 to 2030
3.4 Lipid Market Outlook by Application, $ Million, 2021 to 2030
3.5 Lipid Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Lipid Industry
4.2 Key Market Trends in Lipid Industry
4.3 Potential Opportunities in Lipid Industry
4.4 Key Challenges in Lipid Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Lipid Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Lipid Market Outlook by Segments
7.1 Lipid Market Outlook by Segments, $ Million, 2021- 2030
By Product & Service
Assay Kits
Instruments
Services
By Circulating Biomarker
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Extracellular Vesicles
Others
By Clinical Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring
By Technology
Multi-gene Parallel Analysis using NGS
Single-gene Analysis using PCR
By Application
Cancer Applications
-Lung Cancer
-Breast Cancer
-Colorectal Cancer
-Prostate Cancer
-Melanoma
-Others
Non-cancer Applications
-Non-Invasive Prenatal Testing
-Organ Transplantation
-Infectious Disease Testing
By End-User
Reference Laboratories
Hospitals and Physician Laboratories
Academic & Research Centers
Others
8 North America Lipid Market Analysis and Outlook To 2030
8.1 Introduction to North America Lipid Markets in 2024
8.2 North America Lipid Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Lipid Market size Outlook by Segments, 2021-2030
By Product & Service
Assay Kits
Instruments
Services
By Circulating Biomarker
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Extracellular Vesicles
Others
By Clinical Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring
By Technology
Multi-gene Parallel Analysis using NGS
Single-gene Analysis using PCR
By Application
Cancer Applications
-Lung Cancer
-Breast Cancer
-Colorectal Cancer
-Prostate Cancer
-Melanoma
-Others
Non-cancer Applications
-Non-Invasive Prenatal Testing
-Organ Transplantation
-Infectious Disease Testing
By End-User
Reference Laboratories
Hospitals and Physician Laboratories
Academic & Research Centers
Others
9 Europe Lipid Market Analysis and Outlook To 2030
9.1 Introduction to Europe Lipid Markets in 2024
9.2 Europe Lipid Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Lipid Market Size Outlook by Segments, 2021-2030
By Product & Service
Assay Kits
Instruments
Services
By Circulating Biomarker
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Extracellular Vesicles
Others
By Clinical Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring
By Technology
Multi-gene Parallel Analysis using NGS
Single-gene Analysis using PCR
By Application
Cancer Applications
-Lung Cancer
-Breast Cancer
-Colorectal Cancer
-Prostate Cancer
-Melanoma
-Others
Non-cancer Applications
-Non-Invasive Prenatal Testing
-Organ Transplantation
-Infectious Disease Testing
By End-User
Reference Laboratories
Hospitals and Physician Laboratories
Academic & Research Centers
Others
10 Asia Pacific Lipid Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Lipid Markets in 2024
10.2 Asia Pacific Lipid Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Lipid Market size Outlook by Segments, 2021-2030
By Product & Service
Assay Kits
Instruments
Services
By Circulating Biomarker
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Extracellular Vesicles
Others
By Clinical Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring
By Technology
Multi-gene Parallel Analysis using NGS
Single-gene Analysis using PCR
By Application
Cancer Applications
-Lung Cancer
-Breast Cancer
-Colorectal Cancer
-Prostate Cancer
-Melanoma
-Others
Non-cancer Applications
-Non-Invasive Prenatal Testing
-Organ Transplantation
-Infectious Disease Testing
By End-User
Reference Laboratories
Hospitals and Physician Laboratories
Academic & Research Centers
Others
11 South America Lipid Market Analysis and Outlook To 2030
11.1 Introduction to South America Lipid Markets in 2024
11.2 South America Lipid Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Lipid Market size Outlook by Segments, 2021-2030
By Product & Service
Assay Kits
Instruments
Services
By Circulating Biomarker
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Extracellular Vesicles
Others
By Clinical Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring
By Technology
Multi-gene Parallel Analysis using NGS
Single-gene Analysis using PCR
By Application
Cancer Applications
-Lung Cancer
-Breast Cancer
-Colorectal Cancer
-Prostate Cancer
-Melanoma
-Others
Non-cancer Applications
-Non-Invasive Prenatal Testing
-Organ Transplantation
-Infectious Disease Testing
By End-User
Reference Laboratories
Hospitals and Physician Laboratories
Academic & Research Centers
Others
12 Middle East and Africa Lipid Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Lipid Markets in 2024
12.2 Middle East and Africa Lipid Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Lipid Market size Outlook by Segments, 2021-2030
By Product & Service
Assay Kits
Instruments
Services
By Circulating Biomarker
Circulating Tumor Cells
Circulating Tumor DNA
Cell-free DNA
Extracellular Vesicles
Others
By Clinical Application
Early Cancer Screening
Therapy Selection
Treatment Monitoring
Recurrence Monitoring
By Technology
Multi-gene Parallel Analysis using NGS
Single-gene Analysis using PCR
By Application
Cancer Applications
-Lung Cancer
-Breast Cancer
-Colorectal Cancer
-Prostate Cancer
-Melanoma
-Others
Non-cancer Applications
-Non-Invasive Prenatal Testing
-Organ Transplantation
-Infectious Disease Testing
By End-User
Reference Laboratories
Hospitals and Physician Laboratories
Academic & Research Centers
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
Biocept Inc
Bio-Rad Laboratories Inc
Exact Sciences Corp
F. Hoffmann-La Roche Ltd
Guardant Health
Illumina Inc
Mdxhealth
Myriad Genetics Inc
Natera Inc
Personalis Inc
Qiagen
Sysmex Corp
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product & Service
By Circulating Biomarker
By Clinical Application
By Technology
By Application
By End-User
Countries Analyzed
The Global Liquid Biopsy Market Size is estimated at $5.7 Billion in 2025 and is forecast to register an annual growth rate (CAGR) of 12.4% to reach $16.3 Billion by 2034.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Biocept Inc, Bio-Rad Laboratories Inc, Exact Sciences Corp, F. Hoffmann-La Roche Ltd, Guardant Health, Illumina Inc, Mdxhealth, Myriad Genetics Inc, Natera Inc, Personalis Inc, Qiagen, Sysmex Corp, Thermo Fisher Scientific Inc
Base Year- 2024; Estimated Year- 2025; Historic Period- 2019-2024; Forecast period- 2025 to 2034; Currency: Revenue (USD); Volume